Drug-Induced Parkinsonism and Tardive Dyskinesia in Rats Chronically Treated with Haloperidol
Objective: To reproduce the side effects of antipsychotic drugs (drug-induced Parkinsonism and tardive dyskinesia) in rats and elucidate its pathomechanism by examining morphological changes in…GPR30 agonists attenuate haloperidol-induced neurotoxicity in SH-SY5Y cells and adult zebrafish.
Objective: Objective:1. To investigate the neuroprotective effect of FDA-approved compounds (Raloxifene and Fulvestrant) against haloperidol-induced neurotoxicity in SHSY-5Y cells and adult zebrafish2. To explore the molecular…Bistriatal hypermetabolism on 18-FDG PET-CT in tardive dyskinesia
Objective: Tardive dyskinesia (TD) describes various movement disorders developing after treatment with dopamine receptor blocking agents (DRBA), including stereotypy, akathisia, dystonia, tremor, tics and chorea.…Tardive Dystonia Following Risperidone Treatment : A Case Report and Therapeutic Approach
Objective: To report a case of tardive dystonia induced by risperidone and discuss the therapeutic approach, including the use of botulinum toxin. Background: Risperidone, a…Comorbid Tardive Dyskinesia (TD) and Restless Leg Syndrome (RLS)
Objective: To describe an unusual co-occurrence of disorders involving dopaminergic dysregulation. Background: TD and RLS result from opposing abnormalities in dopaminergic transmission pathways in the…Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report
Objective: To underscore the rarity of tardive dyskinesia manifestation in a schizophrenic patient, prescribed second-generation DRBA agents, quetiapine and SSRI sertraline. Background: Tardive dyskinesia is…Oromandibular Dystonia in Hashimoto Encephalopathy: An Unusual Association Not To Miss
Objective: To describe a case of proven Hashimoto Encephalopathy presenting with oromandibular dystonia (OMD) and orofacial dyskinesias (OFD) Background: Neurologic manifestations of Hashimoto’s Encephalopathy (HE)…Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: A Post-Hoc Analysis of Phase 3 Clinical Trial Data
Objective: To assess the treatment effect size of once-daily valbenazine for tardive dyskinesia (TD) and for chorea associated with Huntington’s disease (HD) using data from…Trajectories of Tardive Dyskinesia Impact Scale (TDIS) and Abnormal Involuntary Movement Scale (AIMS) over time with valbenazine treatment
Objective: To assess TDIS and global AIMS measures change trajectories using data from KINECT-4, an open-label 52-week trial assessing valbenazine in TD [1] Background: AIMS…Burden and management of tardive dyskinesia (TD): a cross-sectional international survey study to assess the perceptions and experiences of patients with TD
Objective: To assess patient perceptions of and experiences with TD and its impact on their daily functioning and quality of life (QoL). Background: There is…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 9
- Next Page »